Skip to navigation Skip to content



Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progressive MS

October 18, 2017

  • A special issue of Multiple Sclerosis Journal, sponsored by the International Progressive MS Alliance, has been published, containing ten papers that review the challenges and the potential solutions to improving clinical trials and their outcomes so that new treatments become available for people living with progressive MS.
  • Progressive MS is a form of MS that gets worse over time. Each day, progressive MS takes things away from people: vision, mobility, cognition, ability to work, and their very independence. MS is found in every country where studies have been conducted, and more than 2.3 million people worldwide currently live with the disease; over 1 million people live with a progressive form of MS.
  • The special issue includes articles on many aspects of trial design, lessons learned, and research gaps, and includes a paper by a person living with MS, urging researchers to involve people with MS in every stage of planning and conducting clinical trials so that they are relevant to the treatment needs of people with progressive MS.
  • As a result of the sponsorship by the Alliance, the full content of the special issue, “Advancing Trial Design In Progressive Multiple Sclerosis,” may be read by anyone by following links below.
  • The papers stemmed from participants involved in a workshop convened in Rome in March 2017 under the auspices of the European Committee for Treatment and Research in MS (ECTRIMS) and the International Progressive MS Alliance.
  • Together, the papers provide a comprehensive roadmap for planning and conducting clinical trials and further research needed to develop new therapies that can slow or stop progressive MS. 

Special Issue: Advancing Trial Design In Progressive Multiple Sclerosis

Guest Editors: Jeremy Chataway and Robert Fox
DH Miller and AJ Thompson

RJ Fox and J Chataway

--The evolving role of people with MS in clinical research— Some progress but more is needed
K Smith

--Progressive MS trials: Lessons learned
C Tur and X Montalban

--Targets of therapy in progressive MS
H Lassmann

--Fluid biomarker and electrophysiological outcome measures for progressive
MS trials

C Barro, L Leocani, D Leppert, G Comi, L Kappos and J Kuhle

--Imaging outcome measures for progressive multiple sclerosis trials
M Moccia, N de Stefano and F Barkhof

--Clinical outcome measures for progressive MS trials
D Ontaneda, JA Cohen and MP Amato

--Patient selection for trials
JS Wolinsky

--Clinical trial design for progressive MS trials
M Pardini, G Cutter and MP Sormani

--‘Progressive MS – macro views’: The need for novel clinical trial paradigms to enable drug development for progressive MS
P Zaratin, G Comi and D Leppert

Ending progressive MS is an urgent and unmet need that must be overcome so that people affected by MS can live their lives without the uncertainty of what tomorrow will bring. The International Progressive MS Alliance is an unprecedented international initiative that is connecting resources and experts around the world to find answers and develop solutions to end progressive MS. The goal of the Alliance is to speed the development of new treatments for progressive MS by funding the best research, wherever it exists.
Read more about the International Progressive MS Alliance
Read more about research on progressive MS

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.